Association of MDM2 SNP309, age of onset, and gender in cutaneous melanoma

Elnaz F. Firoz, Melanie Warycha, Jan Zakrzewski, Danuta Pollens, Guimin Wang, Richard Shapiro, Russell Berman, Anna Pavlick, Prashiela Manga, Harry Ostrer, Julide Tok Celebi, Hideko Kamino, Farbod Darvishian, Linda Rolnitzky, Judith D. Goldberg, Iman Osman, David Polsky

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Purpose: In certain cancers, MDM2 SNP309 has been associated with early tumor onset in women. In melanoma, incidence rates are higher in women than in men among individuals less than 40 years of age, but among those older than 50 years of age, melanoma is more frequent in men than in women. To investigate this difference, we examined the association among MDM2 SNP309, age at diagnosis, and gender among melanoma patients. Experimental Design: Prospectively enrolled melanoma patients (N = 227) were evaluated for MDM2 SNP309 and the related polymorphism, p53 Arg72Pro. DNAwas isolated from patient blood samples, and genotypes were analyzed by PCR-restriction fragment length polymorphism. Associations among MDM2 SNP309, p53 Arg72Pro, age at diagnosis, and clinicopathologic features of melanoma were analyzed. Results: The median age at diagnosis was 13 years earlier among women with a SNP309 GG genotype (46 years) compared with women with TG+TT genotypes (59 years; P = 0.19). Analyses using age dichotomized at each decade indicated that women with a GG genotype had significantly higher risks of being diagnosed with melanoma at ages <50 years compared with women ≥50 years, but not when the comparison was made between women <60 and ≥60 years. At ages <50 years, women with a GG genotype had a 3.89 times greater chance of being diagnosed compared with women with TG+TT genotypes (P = 0.01). Similar observations were not seen among men. Conclusions: Our data suggest that MDM2 may play an important role in the development of melanoma in women. The MDM2 SNP309 genotype may help identify women at risk of developing melanoma at a young age.

Original languageEnglish (US)
Pages (from-to)2573-2580
Number of pages8
JournalClinical Cancer Research
Volume15
Issue number7
DOIs
StatePublished - Apr 1 2009
Externally publishedYes

Fingerprint

Age of Onset
Melanoma
Skin
Genotype
Restriction Fragment Length Polymorphisms
Neoplasms
Research Design
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Firoz, E. F., Warycha, M., Zakrzewski, J., Pollens, D., Wang, G., Shapiro, R., ... Polsky, D. (2009). Association of MDM2 SNP309, age of onset, and gender in cutaneous melanoma. Clinical Cancer Research, 15(7), 2573-2580. https://doi.org/10.1158/1078-0432.CCR-08-2678

Association of MDM2 SNP309, age of onset, and gender in cutaneous melanoma. / Firoz, Elnaz F.; Warycha, Melanie; Zakrzewski, Jan; Pollens, Danuta; Wang, Guimin; Shapiro, Richard; Berman, Russell; Pavlick, Anna; Manga, Prashiela; Ostrer, Harry; Celebi, Julide Tok; Kamino, Hideko; Darvishian, Farbod; Rolnitzky, Linda; Goldberg, Judith D.; Osman, Iman; Polsky, David.

In: Clinical Cancer Research, Vol. 15, No. 7, 01.04.2009, p. 2573-2580.

Research output: Contribution to journalArticle

Firoz, EF, Warycha, M, Zakrzewski, J, Pollens, D, Wang, G, Shapiro, R, Berman, R, Pavlick, A, Manga, P, Ostrer, H, Celebi, JT, Kamino, H, Darvishian, F, Rolnitzky, L, Goldberg, JD, Osman, I & Polsky, D 2009, 'Association of MDM2 SNP309, age of onset, and gender in cutaneous melanoma', Clinical Cancer Research, vol. 15, no. 7, pp. 2573-2580. https://doi.org/10.1158/1078-0432.CCR-08-2678
Firoz EF, Warycha M, Zakrzewski J, Pollens D, Wang G, Shapiro R et al. Association of MDM2 SNP309, age of onset, and gender in cutaneous melanoma. Clinical Cancer Research. 2009 Apr 1;15(7):2573-2580. https://doi.org/10.1158/1078-0432.CCR-08-2678
Firoz, Elnaz F. ; Warycha, Melanie ; Zakrzewski, Jan ; Pollens, Danuta ; Wang, Guimin ; Shapiro, Richard ; Berman, Russell ; Pavlick, Anna ; Manga, Prashiela ; Ostrer, Harry ; Celebi, Julide Tok ; Kamino, Hideko ; Darvishian, Farbod ; Rolnitzky, Linda ; Goldberg, Judith D. ; Osman, Iman ; Polsky, David. / Association of MDM2 SNP309, age of onset, and gender in cutaneous melanoma. In: Clinical Cancer Research. 2009 ; Vol. 15, No. 7. pp. 2573-2580.
@article{792aef6726a445e886fd2bad7fc7a1e9,
title = "Association of MDM2 SNP309, age of onset, and gender in cutaneous melanoma",
abstract = "Purpose: In certain cancers, MDM2 SNP309 has been associated with early tumor onset in women. In melanoma, incidence rates are higher in women than in men among individuals less than 40 years of age, but among those older than 50 years of age, melanoma is more frequent in men than in women. To investigate this difference, we examined the association among MDM2 SNP309, age at diagnosis, and gender among melanoma patients. Experimental Design: Prospectively enrolled melanoma patients (N = 227) were evaluated for MDM2 SNP309 and the related polymorphism, p53 Arg72Pro. DNAwas isolated from patient blood samples, and genotypes were analyzed by PCR-restriction fragment length polymorphism. Associations among MDM2 SNP309, p53 Arg72Pro, age at diagnosis, and clinicopathologic features of melanoma were analyzed. Results: The median age at diagnosis was 13 years earlier among women with a SNP309 GG genotype (46 years) compared with women with TG+TT genotypes (59 years; P = 0.19). Analyses using age dichotomized at each decade indicated that women with a GG genotype had significantly higher risks of being diagnosed with melanoma at ages <50 years compared with women ≥50 years, but not when the comparison was made between women <60 and ≥60 years. At ages <50 years, women with a GG genotype had a 3.89 times greater chance of being diagnosed compared with women with TG+TT genotypes (P = 0.01). Similar observations were not seen among men. Conclusions: Our data suggest that MDM2 may play an important role in the development of melanoma in women. The MDM2 SNP309 genotype may help identify women at risk of developing melanoma at a young age.",
author = "Firoz, {Elnaz F.} and Melanie Warycha and Jan Zakrzewski and Danuta Pollens and Guimin Wang and Richard Shapiro and Russell Berman and Anna Pavlick and Prashiela Manga and Harry Ostrer and Celebi, {Julide Tok} and Hideko Kamino and Farbod Darvishian and Linda Rolnitzky and Goldberg, {Judith D.} and Iman Osman and David Polsky",
year = "2009",
month = "4",
day = "1",
doi = "10.1158/1078-0432.CCR-08-2678",
language = "English (US)",
volume = "15",
pages = "2573--2580",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Association of MDM2 SNP309, age of onset, and gender in cutaneous melanoma

AU - Firoz, Elnaz F.

AU - Warycha, Melanie

AU - Zakrzewski, Jan

AU - Pollens, Danuta

AU - Wang, Guimin

AU - Shapiro, Richard

AU - Berman, Russell

AU - Pavlick, Anna

AU - Manga, Prashiela

AU - Ostrer, Harry

AU - Celebi, Julide Tok

AU - Kamino, Hideko

AU - Darvishian, Farbod

AU - Rolnitzky, Linda

AU - Goldberg, Judith D.

AU - Osman, Iman

AU - Polsky, David

PY - 2009/4/1

Y1 - 2009/4/1

N2 - Purpose: In certain cancers, MDM2 SNP309 has been associated with early tumor onset in women. In melanoma, incidence rates are higher in women than in men among individuals less than 40 years of age, but among those older than 50 years of age, melanoma is more frequent in men than in women. To investigate this difference, we examined the association among MDM2 SNP309, age at diagnosis, and gender among melanoma patients. Experimental Design: Prospectively enrolled melanoma patients (N = 227) were evaluated for MDM2 SNP309 and the related polymorphism, p53 Arg72Pro. DNAwas isolated from patient blood samples, and genotypes were analyzed by PCR-restriction fragment length polymorphism. Associations among MDM2 SNP309, p53 Arg72Pro, age at diagnosis, and clinicopathologic features of melanoma were analyzed. Results: The median age at diagnosis was 13 years earlier among women with a SNP309 GG genotype (46 years) compared with women with TG+TT genotypes (59 years; P = 0.19). Analyses using age dichotomized at each decade indicated that women with a GG genotype had significantly higher risks of being diagnosed with melanoma at ages <50 years compared with women ≥50 years, but not when the comparison was made between women <60 and ≥60 years. At ages <50 years, women with a GG genotype had a 3.89 times greater chance of being diagnosed compared with women with TG+TT genotypes (P = 0.01). Similar observations were not seen among men. Conclusions: Our data suggest that MDM2 may play an important role in the development of melanoma in women. The MDM2 SNP309 genotype may help identify women at risk of developing melanoma at a young age.

AB - Purpose: In certain cancers, MDM2 SNP309 has been associated with early tumor onset in women. In melanoma, incidence rates are higher in women than in men among individuals less than 40 years of age, but among those older than 50 years of age, melanoma is more frequent in men than in women. To investigate this difference, we examined the association among MDM2 SNP309, age at diagnosis, and gender among melanoma patients. Experimental Design: Prospectively enrolled melanoma patients (N = 227) were evaluated for MDM2 SNP309 and the related polymorphism, p53 Arg72Pro. DNAwas isolated from patient blood samples, and genotypes were analyzed by PCR-restriction fragment length polymorphism. Associations among MDM2 SNP309, p53 Arg72Pro, age at diagnosis, and clinicopathologic features of melanoma were analyzed. Results: The median age at diagnosis was 13 years earlier among women with a SNP309 GG genotype (46 years) compared with women with TG+TT genotypes (59 years; P = 0.19). Analyses using age dichotomized at each decade indicated that women with a GG genotype had significantly higher risks of being diagnosed with melanoma at ages <50 years compared with women ≥50 years, but not when the comparison was made between women <60 and ≥60 years. At ages <50 years, women with a GG genotype had a 3.89 times greater chance of being diagnosed compared with women with TG+TT genotypes (P = 0.01). Similar observations were not seen among men. Conclusions: Our data suggest that MDM2 may play an important role in the development of melanoma in women. The MDM2 SNP309 genotype may help identify women at risk of developing melanoma at a young age.

UR - http://www.scopus.com/inward/record.url?scp=65249160573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65249160573&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-08-2678

DO - 10.1158/1078-0432.CCR-08-2678

M3 - Article

VL - 15

SP - 2573

EP - 2580

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 7

ER -